Clin Mol Hepatol > Volume 30(2); 2024 > Article |
|
Events | Studies (n) | Participants (n) | Events (n) | Incidence rate per 1,000 person-years (95% CI) | I2 (%)* |
---|---|---|---|---|---|
Mortality | |||||
All-cause | 37 | 513,409 | 75,371 | 14.57 (11.45–17.69) | 99.9 |
Cardiovascular disease-related | 23 | 116,656 | 2,240 | 4.53 (2.92–6.15) | 99.0 |
Non-liver cancer related | 22 | 116,949 | 2,239 | 3.27 (2.38–4.15) | 98.7 |
Liver-related | 26 | 118,005 | 912 | 3.10 (1.96–4.24) | 97.0 |
Liver-related events | |||||
Any event | 40 | 603,907 | 108,512 | 24.28 (13.98–34.58) | 100.0 |
Fibrosis progression | 5 | 1,098 | 253 | 48.95 (22.86–75.04) | 92.8 |
Cirrhosis (compensated + decompensated) | 21 | 309,694 | 5,370 | 10.85 (6.65–15.06) | 99.5 |
Liver transplant | 10 | 3,503 | 126 | 11.99 (0.00–28.26) | 92.3 |
HCC | 30 | 336,845 | 1,025 | 3.39 (1.97–4.81) | 94.6 |
Cirrhotic decompensation | |||||
Any decompensation | 16 | 131,983 | 3,136 | 12.08 (6.80–17.36) | 98.3 |
Ascites | 13 | 4,764 | 201 | 6.68 (2.75–10.61) | 90.7 |
Varices/variceal bleeding | 11 | 4,318 | 139 | 4.72 (2.57–6.87) | 83.0 |
Hepatic Encephalopathy | 8 | 3,462 | 58 | 2.31 (1.07–3.55) | 72.0 |
Metabolic outcomes (in people without metabolic disease at baseline) | |||||
Metabolic syndrome | 3 | 535 | 151 | 25.40 (0.00–68.87) | 98.6 |
Hypertension | 12 | 5,591 | 922 | 25.84 (14.47–37.21) | 98.4 |
Hyperlipidemia/Dyslipidemia | 7 | 9,549 | 885 | 26.43 (11.38–41.47) | 98.4 |
Diabetes mellitus* | 24 | 39,562 | 5,025 | 19.01 (15.01–23.03) | 98.4 |
Cardiovascular events (in people without cardiovascular disease at baseline) | |||||
Any event | 19 | 188,368 | 11,222 | 24.77 (8.46–41.08) | 99.8 |
Coronary artery disease/congestive heart failure | 8 | 27,706 | 3,695 | 40.12 (2.13–78.11) | 98.3 |
Myocardial infarction | 9 | 185,174 | 1,974 | 7.07 (0.00–14.90) | 99.0 |
Stroke (ischemic/hemorrhagic) | 10 | 148,571 | 3,602 | 8.05 (0.51–15.59) | 92.5 |
Renal events | 6 | 330,872 | 14,712 | 30.28 (0.00–70.87) | 99.8 |
Depression/anxiety | 1 | 19,871 | 5,783 | 29.10 (28.35–29.85) | N/A |
Non-liver cancer | 11 | 29,243 | 3,165 | 10.49 (8.41–12.56) | 96.5 |
Mindie H. Nguyen
https://orcid.org/0000-0002-6275-4989
The effect of moderate alcohol consumption on nonalcoholic fatty liver disease2023 April;29(2)